ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

The green day-ahead market (G-DAM) has a weighted average price of ₹4.07 per unit during the period under review.

Application error: a client-side exception has occurred (see the browser console for more information).

The business reported a Net Interest Income (NII) registered a growth of 1.5% to ₹42,774 Crore versus ₹41,655 Crore in Q4FY24.

Tata Motors Limited announced that its board committee has nodded to an issue of non-convertible debentures (NCDs) worth up ...

As per RBI’s latest data release, credit growth dipped sharply in April. From 10.9% YoY growth at the beginning of April, it ...

The new capacity addition is part of UltraTech's strategic growth strategy to cater to growing cement demand in domestic as ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

The company's current performance is also a reflection of the overall Indian EV ecosystem change, and there is a certain ...

The company's domestic sales stood at 8,148 units, 4.1% lower than 8,492 tractors sold in the domestic market during last ...

Two-wheeler exports brought some relief with the volume of export rising 4% YoY at 1,29,322 units in April 2025 ...

Zomato’s consolidated revenue for the quarter was reported at ₹5,833 Crore, versus ₹3,562 Crore in the previous corresponding ...